Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Nonalcoholic Steatohepatitis (NASH) market report explains the definition, types, applications, major countries, and major players of the Nonalcoholic Steatohepatitis (NASH) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Gilead Sciences
Intercept Pharmaceuticals
Tobira Therapeutics
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Genfit
Cadila Healthcare
Novartis International
Gemphire Therapeutics
Shire
By Type:
Vitamin E & Pioglitazone
Ocaliva
Elafibranor
Selonsertib & Cenicriviroc
By End-User:
Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Nonalcoholic Steatohepatitis (NASH) Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Nonalcoholic Steatohepatitis (NASH) Outlook to 2028- Original Forecasts
-
2.2 Nonalcoholic Steatohepatitis (NASH) Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Nonalcoholic Steatohepatitis (NASH) Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Nonalcoholic Steatohepatitis (NASH) Market- Recent Developments
-
6.1 Nonalcoholic Steatohepatitis (NASH) Market News and Developments
-
6.2 Nonalcoholic Steatohepatitis (NASH) Market Deals Landscape
7 Nonalcoholic Steatohepatitis (NASH) Raw Materials and Cost Structure Analysis
-
7.1 Nonalcoholic Steatohepatitis (NASH) Key Raw Materials
-
7.2 Nonalcoholic Steatohepatitis (NASH) Price Trend of Key Raw Materials
-
7.3 Nonalcoholic Steatohepatitis (NASH) Key Suppliers of Raw Materials
-
7.4 Nonalcoholic Steatohepatitis (NASH) Market Concentration Rate of Raw Materials
-
7.5 Nonalcoholic Steatohepatitis (NASH) Cost Structure Analysis
-
7.5.1 Nonalcoholic Steatohepatitis (NASH) Raw Materials Analysis
-
7.5.2 Nonalcoholic Steatohepatitis (NASH) Labor Cost Analysis
-
7.5.3 Nonalcoholic Steatohepatitis (NASH) Manufacturing Expenses Analysis
8 Global Nonalcoholic Steatohepatitis (NASH) Import and Export Analysis (Top 10 Countries)
-
8.1 Global Nonalcoholic Steatohepatitis (NASH) Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Nonalcoholic Steatohepatitis (NASH) Export by Region (Top 10 Countries) (2017-2028)
9 Global Nonalcoholic Steatohepatitis (NASH) Market Outlook by Types and Applications to 2022
-
9.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Vitamin E & Pioglitazone Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Ocaliva Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Elafibranor Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Selonsertib & Cenicriviroc Consumption and Growth Rate (2017-2022)
-
9.2 Global Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Online Provider Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Nonalcoholic Steatohepatitis (NASH) Market Analysis and Outlook till 2022
-
10.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.2.2 Canada Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.2.3 Mexico Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.2 UK Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.3 Spain Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.4 Belgium Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.5 France Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.6 Italy Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.7 Denmark Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.8 Finland Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.9 Norway Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.10 Sweden Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.11 Poland Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.12 Russia Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.3.13 Turkey Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.2 Japan Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.3 India Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.4 South Korea Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.5 Pakistan Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.6 Bangladesh Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.7 Indonesia Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.8 Thailand Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.9 Singapore Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.10 Malaysia Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.11 Philippines Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.4.12 Vietnam Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.2 Colombia Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.3 Chile Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.4 Argentina Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.5 Venezuela Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.6 Peru Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.7 Puerto Rico Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.5.8 Ecuador Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.6.2 Kuwait Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.6.3 Oman Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.6.4 Qatar Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.6.5 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.6.6 United Arab Emirates Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.7.2 South Africa Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.7.3 Egypt Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.7.4 Algeria Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
-
10.8.2 New Zealand Nonalcoholic Steatohepatitis (NASH) Consumption (2017-2022)
11 Global Nonalcoholic Steatohepatitis (NASH) Competitive Analysis
-
11.1 Gilead Sciences
-
11.1.1 Gilead Sciences Company Details
-
11.1.2 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.1.4 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Intercept Pharmaceuticals
-
11.2.1 Intercept Pharmaceuticals Company Details
-
11.2.2 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.2.4 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Tobira Therapeutics
-
11.3.1 Tobira Therapeutics Company Details
-
11.3.2 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.3.4 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Conatus Pharmaceuticals
-
11.4.1 Conatus Pharmaceuticals Company Details
-
11.4.2 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.4.4 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Galmed Pharmaceuticals
-
11.5.1 Galmed Pharmaceuticals Company Details
-
11.5.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.5.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Genfit
-
11.6.1 Genfit Company Details
-
11.6.2 Genfit Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Genfit Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.6.4 Genfit Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Cadila Healthcare
-
11.7.1 Cadila Healthcare Company Details
-
11.7.2 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.7.4 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Novartis International
-
11.8.1 Novartis International Company Details
-
11.8.2 Novartis International Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Novartis International Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.8.4 Novartis International Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Gemphire Therapeutics
-
11.9.1 Gemphire Therapeutics Company Details
-
11.9.2 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.9.4 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Shire
-
11.10.1 Shire Company Details
-
11.10.2 Shire Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Shire Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
11.10.4 Shire Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Nonalcoholic Steatohepatitis (NASH) Market Outlook by Types and Applications to 2028
-
12.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Vitamin E & Pioglitazone Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Ocaliva Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Elafibranor Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Selonsertib & Cenicriviroc Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Online Provider Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Nonalcoholic Steatohepatitis (NASH) Market Analysis and Outlook to 2028
-
13.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.2.2 Canada Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.2.3 Mexico Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.2 UK Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.3 Spain Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.4 Belgium Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.5 France Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.6 Italy Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.7 Denmark Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.8 Finland Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.9 Norway Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.10 Sweden Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.11 Poland Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.12 Russia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.3.13 Turkey Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.2 Japan Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.3 India Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.4 South Korea Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.8 Thailand Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.9 Singapore Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.11 Philippines Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.2 Colombia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.3 Chile Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.4 Argentina Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.6 Peru Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.6.3 Oman Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.6.4 Qatar Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.7.2 South Africa Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.7.3 Egypt Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.7.4 Algeria Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Nonalcoholic Steatohepatitis (NASH) Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Nonalcoholic Steatohepatitis (NASH)
-
Figure of Nonalcoholic Steatohepatitis (NASH) Picture
-
Table Global Nonalcoholic Steatohepatitis (NASH) Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Nonalcoholic Steatohepatitis (NASH) Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Vitamin E & Pioglitazone Consumption and Growth Rate (2017-2022)
-
Figure Global Ocaliva Consumption and Growth Rate (2017-2022)
-
Figure Global Elafibranor Consumption and Growth Rate (2017-2022)
-
Figure Global Selonsertib & Cenicriviroc Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Online Provider Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Table North America Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure United States Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Canada Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Mexico Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table Europe Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure Germany Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure UK Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Spain Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Belgium Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure France Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Italy Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Denmark Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Finland Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Norway Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Sweden Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Poland Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Russia Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Turkey Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table APAC Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure China Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Japan Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure India Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure South Korea Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Thailand Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Singapore Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Philippines Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table South America Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure Brazil Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Colombia Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Chile Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Argentina Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Peru Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table GCC Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure Bahrain Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Oman Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Qatar Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table Africa Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure Nigeria Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure South Africa Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Egypt Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure Algeria Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table Oceania Nonalcoholic Steatohepatitis (NASH) Consumption by Country (2017-2022)
-
Figure Australia Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Nonalcoholic Steatohepatitis (NASH) Consumption and Growth Rate (2017-2022)
-
Table Gilead Sciences Company Details
-
Table Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Intercept Pharmaceuticals Company Details
-
Table Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Tobira Therapeutics Company Details
-
Table Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Conatus Pharmaceuticals Company Details
-
Table Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Galmed Pharmaceuticals Company Details
-
Table Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Genfit Company Details
-
Table Genfit Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genfit Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Genfit Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Cadila Healthcare Company Details
-
Table Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Novartis International Company Details
-
Table Novartis International Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis International Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Novartis International Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Gemphire Therapeutics Company Details
-
Table Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Table Shire Company Details
-
Table Shire Nonalcoholic Steatohepatitis (NASH) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shire Nonalcoholic Steatohepatitis (NASH) Main Business and Markets Served
-
Table Shire Nonalcoholic Steatohepatitis (NASH) Product Portfolio
-
Figure Global Vitamin E & Pioglitazone Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ocaliva Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Elafibranor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Selonsertib & Cenicriviroc Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Provider Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Table North America Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure United States Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure Germany Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure China Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure Brazil Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Nonalcoholic Steatohepatitis (NASH) Consumption Forecast by Country (2022-2028)
-
Figure Australia Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Nonalcoholic Steatohepatitis (NASH) Consumption Forecast and Growth Rate (2022-2028)
-
